272 related articles for article (PubMed ID: 24514424)
1. Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia.
Celton M; Forest A; Gosse G; Lemieux S; Hebert J; Sauvageau G; Wilhelm BT
Leukemia; 2014 Aug; 28(8):1617-26. PubMed ID: 24514424
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
[TBL] [Abstract][Full Text] [Related]
3. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
4. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
[TBL] [Abstract][Full Text] [Related]
5. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
6. GATA2 rs2335052 and GATA2 rs78245253 single-nucleotide polymorphisms in Chinese patients with acute myelocytic leukemia.
Fang F; Xu J; Kang Y; Ren H; Muyey DM; Chen X; Tan Y; Xu Z; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):1491-1500. PubMed ID: 34374210
[TBL] [Abstract][Full Text] [Related]
7. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
8. Human leukemia mutations corrupt but do not abrogate GATA-2 function.
Katsumura KR; Mehta C; Hewitt KJ; Soukup AA; Fraga de Andrade I; Ranheim EA; Johnson KD; Bresnick EH
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10109-E10118. PubMed ID: 30301799
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.
Park SH; Choi JC; Kim SY; Yi J; Oh SH; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Biomed Res Int; 2015; 2015():723682. PubMed ID: 25650308
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
11. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
12. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar
Hollink IHIM; van den Ouweland AMW; Beverloo HB; Arentsen-Peters STCJM; Zwaan CM; Wagner A
J Med Genet; 2017 Dec; 54(12):805-808. PubMed ID: 28432085
[TBL] [Abstract][Full Text] [Related]
14. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
15. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.
Hahn CN; Chong CE; Carmichael CL; Wilkins EJ; Brautigan PJ; Li XC; Babic M; Lin M; Carmagnac A; Lee YK; Kok CH; Gagliardi L; Friend KL; Ekert PG; Butcher CM; Brown AL; Lewis ID; To LB; Timms AE; Storek J; Moore S; Altree M; Escher R; Bardy PG; Suthers GK; D'Andrea RJ; Horwitz MS; Scott HS
Nat Genet; 2011 Sep; 43(10):1012-7. PubMed ID: 21892162
[TBL] [Abstract][Full Text] [Related]
16. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.
Kazenwadel J; Secker GA; Liu YJ; Rosenfeld JA; Wildin RS; Cuellar-Rodriguez J; Hsu AP; Dyack S; Fernandez CV; Chong CE; Babic M; Bardy PG; Shimamura A; Zhang MY; Walsh T; Holland SM; Hickstein DD; Horwitz MS; Hahn CN; Scott HS; Harvey NL
Blood; 2012 Feb; 119(5):1283-91. PubMed ID: 22147895
[TBL] [Abstract][Full Text] [Related]
17. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of GATA2 restrains cell proliferation and enhances apoptosis and chemotherapy mediated apoptosis in human GATA2 overexpressing AML cells.
Menendez-Gonzalez JB; Sinnadurai S; Gibbs A; Thomas LA; Konstantinou M; Garcia-Valverde A; Boyer M; Wang Z; Boyd AS; Blair A; Morgan RG; Rodrigues NP
Sci Rep; 2019 Aug; 9(1):12212. PubMed ID: 31434974
[TBL] [Abstract][Full Text] [Related]
20. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
Garg S; Reyes-Palomares A; He L; Bergeron A; Lavallée VP; Lemieux S; Gendron P; Rohde C; Xia J; Jagdhane P; Müller-Tidow C; Lipka DB; Imren S; Humphries RK; Waskow C; Vick B; Jeremias I; Richard-Carpentier G; Hébert J; Sauvageau G; Zaugg JB; Barabé F; Pabst C
Blood; 2019 Jul; 134(3):263-276. PubMed ID: 31076446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
